Ser1653

Site Information
IIRtPPKsPAtPKQL SwissProt Entrez-Gene
Blast this site against: NCBI SwissProt PDB
Site Group ID: 3558882
Available spectra: 2 CST

In vivo Characterization
Methods used to characterize site in vivo:	mass spectrometry ( 1 , 2 , 3 , 4 , 5 , 6 , 7 , 8 , 9 , 10 , 11 , 12 , 14 , 15 , 16 , 17 , 18 , 19 )
Disease tissue studied:	breast cancer ( 6 , 12 ) , breast ductal carcinoma ( 6 ) , HER2 positive breast cancer ( 2 ) , luminal A breast cancer ( 2 ) , luminal B breast cancer ( 2 ) , breast cancer, surrounding tissue ( 2 ) , breast cancer, triple negative ( 2 , 6 ) , lung cancer ( 9 , 10 , 12 ) , non-small cell lung cancer ( 10 , 12 ) , non-small cell lung adenocarcinoma ( 10 ) , non-small cell large cell lung carcinoma ( 10 ) , small-cell lung cancer ( 9 ) , neuroblastoma ( 11 ) , ovarian cancer ( 6 ) , pancreatic ductal adenocarcinoma ( 8 ) , melanoma skin cancer ( 4 )
Relevant cell line - cell type - tissue:	'pancreatic, ductal'-pancreas ( 8 ) , 293 (epithelial) [AT1 (human), transfection, AT1R stable transfected HEK293] ( 17 ) , 293 (epithelial) [AT1 (human), transfection] ( 16 ) , breast ( 2 , 6 ) , BT-20 (breast cell) ( 12 ) , BT-549 (breast cell) ( 12 ) , Calu 6 (pulmonary) ( 12 ) , DMS53 (pulmonary) ( 9 ) , H2009 (pulmonary) ( 12 ) , H2077 (pulmonary) ( 12 ) , H2887 (pulmonary) ( 12 ) , H322M (pulmonary) ( 12 ) , HCC1359 (pulmonary) ( 12 ) , HCC2279 (pulmonary) ( 12 ) , HCC366 (pulmonary) ( 12 ) , HCC4006 (pulmonary) ( 12 ) , HCC78 (pulmonary) ( 10 , 12 ) , HeLa (cervical) ( 1 , 5 , 14 , 15 ) , HOP62 (pulmonary) ( 12 ) , LOU-NH91 (squamous) ( 12 ) , lung ( 9 , 10 ) , MCF-7 (breast cell) ( 3 ) , MDA-MB-231 (breast cell) ( 12 ) , MDA-MB-468 (breast cell) ( 12 ) , NB10 (neural crest) ( 11 ) , NCI-H1395 (pulmonary) ( 12 ) , NCI-H1568 (pulmonary) ( 12 ) , NCI-H157 (pulmonary) ( 12 ) , NCI-H1648 (pulmonary) ( 12 ) , NCI-H1666 (pulmonary) ( 12 ) , NCI-H1781 (pulmonary) ( 10 ) , NCI-H2030 (pulmonary) ( 12 ) , NCI-H2172 (pulmonary) ( 12 ) , NCI-H2228 (pulmonary) ( 10 ) , NCI-H3122 (pulmonary) ( 10 ) , NCI-H322 (pulmonary) ( 12 ) , NCI-H3255 (pulmonary) ( 18 , 19 ) , NCI-H446 (pulmonary) ( 9 ) , NCI-H460 (pulmonary) ( 12 ) , NCI-H526 (pulmonary) ( 9 ) , NCI-H647 (pulmonary) ( 12 ) , NCI-H661 (pulmonary) ( 10 ) , NCI-H69 (pulmonary) ( 9 ) , NCI-H82 (pulmonary) ( 9 ) , NPC (neural crest) ( 11 ) , ovary ( 6 ) , SH-SY5Y (neural crest) [LRRK2 (human), transfection, over-expression of LRRK2(G2019S)] ( 7 ) , WM239A (melanocyte) ( 4 )

Upstream Regulation
Treatments:	LRRK2-IN-1 ( 7 ) , metformin ( 3 )

References
1	Huang H, et al. (2016) Simultaneous Enrichment of Cysteine-containing Peptides and Phosphopeptides Using a Cysteine-specific Phosphonate Adaptable Tag (CysPAT) in Combination with titanium dioxide (TiO2) Chromatography. Mol Cell Proteomics 15, 3282-3296 27281782 Curated Info
2	Mertins P, et al. (2016) Proteogenomics connects somatic mutations to signalling in breast cancer. Nature 534, 55-62 27251275 Curated Info
3	Sacco F, et al. (2016) Deep Proteomics of Breast Cancer Cells Reveals that Metformin Rewires Signaling Networks Away from a Pro-growth State. Cell Syst 2, 159-71 27135362 Curated Info
4	Stuart SA, et al. (2015) A Phosphoproteomic Comparison of B-RAFV600E and MKK1/2 Inhibitors in Melanoma Cells. Mol Cell Proteomics 14, 1599-615 25850435 Curated Info
5	Sharma K, et al. (2014) Ultradeep human phosphoproteome reveals a distinct regulatory nature of Tyr and Ser/Thr-based signaling. Cell Rep 8, 1583-94 25159151 Curated Info
6	Mertins P, et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13, 1690-704 24719451 Curated Info
7	Luerman GC, et al. (2014) Phosphoproteomic evaluation of pharmacological inhibition of leucine-rich repeat kinase 2 reveals significant off-target effects of LRRK-2-IN-1. J Neurochem 128, 561-76 24117733 Curated Info
8	Britton D, et al. (2014) Quantification of pancreatic cancer proteome and phosphorylome: indicates molecular events likely contributing to cancer and activity of drug targets. PLoS One 9, e90948 24670416 Curated Info
9	Rikova K, Hall B (2013) CST Curation Set: 20735, 21162, 30155, 30156, 30157; Year: 2013; Biosample/Treatment: cell line, DMS53, H526, H69, H82, H446; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
10	Rikova K, Hall B (2013) CST Curation Set: 20740, 21167, 30170, 30171, 30172; Year: 2013; Biosample/Treatment: cell line, H2228, H3122, HCC78, H661, H1781; Disease: -; TMT: Y; Specificities of Antibodies Used to Purify Peptides prior to LCMS: pY, p[ST], RXXp[ST], pSQ, p[ST]QG, LXRXXp[ST], p[ST]P Curated Info
11	DeNardo BD, et al. (2013) Quantitative phosphoproteomic analysis identifies activation of the RET and IGF-1R/IR signaling pathways in neuroblastoma. PLoS One 8, e82513 24349301 Curated Info
12	Klammer M, et al. (2012) Phosphosignature predicts dasatinib response in non-small cell lung cancer. Mol Cell Proteomics 11, 651-68 22617229 Curated Info
13	Beli P, et al. (2012) Proteomic Investigations Reveal a Role for RNA Processing Factor THRAP3 in the DNA Damage Response. Mol Cell 46, 212-25 22424773 Curated Info
14	Guo A (2011) CST Curation Set: 11453; Year: 2011; Biosample/Treatment: cell line, HeLa/nocodazole &'\|\|' pervanadate; Disease: cervical adenocarcinoma; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: p[ST]P Antibodies Used to Purify Peptides prior to LCMS: Phospho-PLK Binding Motif (STP) (D73F6) Rabbit mAb Cat#: 5243, PTMScan(R) Phospho-PLK Binding Motif (STP) Immunoaffinity Beads Cat#: 5756 Curated Info
15	Kettenbach AN, et al. (2011) Quantitative phosphoproteomics identifies substrates and functional modules of aurora and polo-like kinase activities in mitotic cells. Sci Signal 4, rs5 21712546 Curated Info
16	Xiao K, et al. (2010) Global phosphorylation analysis of beta-arrestin-mediated signaling downstream of a seven transmembrane receptor (7TMR). Proc Natl Acad Sci U S A 107, 15299-304 20686112 Curated Info
17	Christensen GL, et al. (2010) Quantitative phosphoproteomics dissection of seven-transmembrane receptor signaling using full and biased agonists. Mol Cell Proteomics 9, 1540-53 20363803 Curated Info
18	Possemato A (2009) CST Curation Set: 7406; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Curated Info
19	Possemato A (2009) CST Curation Set: 7405; Year: 2009; Biosample/Treatment: cell line, NCI-H3255/untreated; Disease: non-small cell lung cancer; SILAC: -; Specificities of Antibodies Used to Purify Peptides prior to LCMS: (K/R)XX[ST] Curated Info